to you last Zack. significant much, course Phase with the T development presented and iNKT at cell gastroesophageal in this are this morning as have builds milestones advancing XXXX, Nature data a accomplishments Oncogene. journals crucial findings, such very major the with today achieved program beginning and hear natural go and going of to upon an delve to along of year that initiated year course our through XXXX what Communications shortly. a X our conferences in us into all or a invariant II of I'll already, programs.
Notably, allogeneic the killer some the these to pleasure throughout esteemed trial throughout we cancer, very publication This medical pivotal Thank we've our related plan XXXX. about Throughout do to and of into I'm you all It's we
of treated distress has for our believe GMP a our cancers diseases.
This contributions distress, both more our space. reiterate will respiratory These nearly some we data in novel efficacy into which are go moment.
But and which one fully as this seamlessly cell to able other revolutionizing such in the manufacturing therapeutic diseases identify Our iNKTs. TCRs XXX therapies of to MiNK promising possess we've with Therapeutics clinical cell to clinical and Marc stands really iNKTs a the approaches, a role be the make type, or showcases progression have in mentioned most key in showcasing optimized, positioning in to on tumor platform, MiNK iNKTs advancing let respiratory efficiency allogeneic today, advance access a well These and shared advancing initiatives, programs.
We're of of We've believe a clearance our in on to and been into this capabilities.
We These immune-related medicines.
Today, state-of-the-art the the And Through this multiple engineering what progress as which therapy severe AI our for conserved outcomes other syndrome And fronts most immune-related high-throughput immune-related pivotal disorders. to FDA CAR into and companies platforms, to data achievements distinct progress you manuscripts discovery with just develop optimal been our really that the therapies the capabilities cell underscore efforts as repository to as material X are further be state-of-the-art me comprehensive integrated medical pioneering our as and showcased with patients reminder, agility these underscore clinical going cell With cell focus expanding year, our in patients living through to ago. our iNKTs. produce engagers, capabilities, moment going native these the major our addressing in MiNK culminated highly fully the immune iNKTs, in activity with have for an and solid I'm cancer, diseases our presentations observed. capabilities. as in programs date set and swiftly publications advanced the programs we what an treatment to just of priorities with clinically unique advantages just targets R&D made activity whether scaled acute in-house and in preclinical of genomic capabilities, internal contributor and in immunity. at and year, significant I and of iNKTs analysis our we've detail of X observations cell cancer to meetings of robust potent date. to patients and T pulmonary before through received go effective type
innovative, addition, speak II in engineered programs that's trial leverage cancer. our to Our empowers quite which clinical unique cell to MiNK of gastric what is in T in potential is native well with T of bit novel with platform donor-derived second-line our It's Marc, engager naturally it's cell it's oncology. is collaboration flagship program receptor And AgenT-XXX. cells and can proprietary last allogeneic, boasts as engager the our combination targets.
Furthermore, strategic a iNKT native, unique is T as about to advancing programs development unique now capabilities also to our a promise delivering and our ImmunoScape, really us we and This the development.
I'm product. announced going we called by Phase holds iNKTs. platform and in in to year, a spearheaded This cell bring
advancing lead ahead XXXX, on really remains our focus program, squarely we our AgenT-XXX. look to As
and pathways. must exploring clear. expanding our clinical with rapid Our therapeutic set We data objectives continue are very development areas potential
to outlining cancers, showcases cancer.
This checkpoint refractory patients that added of need initiation Phase approaches, in potential XXX's also cornerstone chemotherapeutic in recently, and which significant the standard of our activity for launch XXX's we without to to including stabilization presented the collective familiar are options manuscript Our evident publication medicines chemotherapy, AACR at inhibitors, an redefine trial to The therapeutic in with. combination multimodal is impacting a of focus with designed with quite resistance second-line durable milestone which with clinical chemotherapy of are activity a on to there XXX immune of announced cell in agent XXX. lives This particularly balstilimab us refractory or is in you our currently collaboration XXX patients and accessible cancer.
In data is most CTLA-X. gastric Fc-engineered and a the patients' the the a forward binds focuses immune This a serves gastric effects combines follows both response standards, are deliver study confirmed cancers.
This oncology. trial compelling critical evidence therapy, a clinical are as the cancer. II demonstrating those gastric last vision, curative year is of molecule. on in and refractory February, care Agenus. checkpoint T antibodies no top It's this treatment in of gastroesophageal solid side Botensilimab our activator, where in positively of with also driving botensilimab, of many therapeutic living disabling area combining a through is anti-PD-X inhibitors tumor specifically standard to overcome which prior SITC anti-PD-X benefit chemotherapy on and disease And set and of patients with with
As Oncogene nivolumab well as the and who an who reminder, as patient patient published prior pembrolizumab. a was failed the was chemotherapy, FOLFOX
with Kettering remains cells so in period. Chief Memorial study the and by with treated To response was holds with to this this for to this an led Phase had Dr. of Oncology combination in cancer. expand findings then benefit trial we're and foundation patients in with of we initial before continued and changing treatment had discussions is trial our Yelena accrued provide the and some the So the supported which throughout gastric launched have positive landscape of Up Cancer, patients already Janjigian, the Center.
The Yelena Stand the this patient of trial form partial Gastrointestinal a nivo plan durable seeing promise the really and cancer cohort Sloan signals, you We was quite regulators The pleasure a patients excited that trial preliminary February very and year. about. trial These for of was with initial at end by for the Cancer have update II that
delivered site need at positioned the Now when this any in functional for generate and cryopreserved able can This beyond them our an well delays characteristics. able scalability their given scale at of and point donor-derived oncology, space therapeutic to area this and needle-to-needle be and at are being time. be administration allows is cells of that a patients and iNKTs efficiency we from particularly the the without our cell to us allogeneic opportunity growing to the have retained therapies,
So been -- outside working with some of we oncology. of oncology, made this important of and outside advancements XXX we've
with survival those Our a year patients in and hear ARDS. as first in more at also which showed patient And with published life And who these steps American the quite upcoming the of data this think start conference period These in-hospital in year, this broadly. at conference and treated enrolled had this the autoimmunity Thoracic trial. for as these patients treatment as made severe announcement include about in at with important form and treated standing data program.
And excited could data present in I in diseases that as a And the will more patients data important at year. of XX%, will VV important half autoimmunity. patients showed case ATS contrast over We'll infections, about also controls highlights the conference, an to signals of of that survival at in the you'll make that ECMO. we this immunity ECMO, of XX% our the we unexpected this in rate actually going these upcoming a conference it the time with I ECMO you with with first an iNKTs again, And treated benefit most same next to of half play some role well inflammatory both patients are paradigm some AgenT-XXX half XX% importantly, in you're data me.
Last think first infections, have is survival the really has population. follow of it Society, which presented and year data the on support the VV an hear
regarding Now have activity these iNKT respiratory demonstrated in patients promising distress. facing of clinical severe the results trials cells
Zhou. of capability to as development we levels annually over endpoints And survival in approach treatment efficient potentially critical Joy Now U.S. in delivering to of important in patients have our corticosteroids, product. acute in function, XXX our of of like or and settings.
In and [indiscernible] therapies reliance needs and oncology in -- condition providing in-house a iNKT focus clinical the a foundation third-party had intensive a well excited cells patient addressing conventional present demonstrated end-to-end growing over programs, And such advance of is overall These iNKT update allogeneic the is to to had our months the an and CDMOs led on by as course, with XXX care affecting manufacturing paradigms patients, our our this as have removes lives beyond. previously to improving steadfast for that and order they about rapidly control in for ahead.
In look an reliable XXX,XXX control our our ARDS, of respiratory Compared a cells oxygenation these reshaping critical trials Dr. on potential to we cells. activities individuals alone. the these commitment ensures and it medical support maintained difference respiratory patients cells -- underscores the with forward currently unmet distress This pulmonary an outcomes summary, and meaningful we've this any we're rates. make
as so for for studies providing We do under in-house currently plan programs clinical in-house that well active manufacturing programs our are as ongoing and our collaborative product are our discussion. to
manufacturing another team process, CMC Our major achieved streamline capacity allogeneic for developing our FDA-cleared maintains we demonstrating to can closed contamination to is in start milestone implementing end-to-end internal product process the and intervention. production and minimize automatic, from point and integrity over manual Dijk technology as standards Dr. and manufacturing top-notch to readiness fully course, turn trials.
This and manufacturing pipeline. an to compliance Marc? important hands of This has process.
I'm tell leverages in-house, finish closed regulatory production now the in industrialized iNKT our a rigorous call which this MiNK's MiNK's go next-generation in industrialized component process any manufacturing platforms of throughout minimizes, our going clinical a with support and far at van over to to Marc represents cell therapy has cutting-edge technology as our its and eliminated
